

Deposit	Patent Deposit Number
A4	PTA-2444
A9	PTA-2443
A10	PTA-2442
C3	PTA-2445

**IN THE CLAIMS:**

Please amend the claims, as follows:

Cancel Claims 1-58, without prejudice.

Add new Claims 59-131, as follows:

--59. (new) A substantially purified antibody comprising a variable heavy (VH) complementarity determining region (CDR)1 having an amino acid sequence of SEQ ID NO:49, 55, 61 or 67, wherein said antibody immunospecifically binds to a TANGO 268 antigen.

60. (new) A substantially purified antibody comprising a VH CDR2 having an amino acid sequence of SEQ ID NO:50, 56, 62 or 68, wherein said antibody immunospecifically binds to a TANGO 268 antigen.

61. (new) A substantially purified antibody comprising a VH CDR3 having an amino acid sequence of SEQ ID NO:51, 57, 63 or 69, wherein said antibody immunospecifically binds to a TANGO 268 antigen.

62. (new) A substantially purified antibody comprising a variable light (VL) CDR1 having an amino acid sequence of SEQ ID NO:52, 58, 64 or 70, wherein said antibody immunospecifically binds to a TANGO 268 antigen.

63. (new) A substantially purified antibody comprising a VL CDR2 having an amino acid sequence of SEQ ID NO:53, 59, 65 or 71 antibody immunospecifically binds to a TANGO 268 antigen.

64. (new) A substantially purified antibody comprising a VL CDR3 having an amino acid sequence of SEQ ID NO:54, 60, 66 or 72, wherein said antibody immunospecifically binds to a TANGO 268 antigen.

65. (new) The antibody of claim 59 further comprising a VH CDR2 having an amino acid sequence of SEQ ID NO:50, 56, 62 or 68.

66. (new) The antibody of claim 59 further comprising a VH CDR3 having an amino acid sequence of SEQ ID NO:51, 57, 63 or 69.

67. (new) The antibody of claim 59 further comprising a VH CDR2 having an amino acid sequence of SEQ ID NO:50, 56, 62 or 68, and a VH CDR3 having an amino acid sequence of SEQ ID NO:51, 57, 63 or 69.

68. (new) The antibody of claim 59 further comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:52, 58, 64 or 70.

69. (new) The antibody of claim 59 further comprising a VL CDR2 having an amino acid sequence of SEQ ID NO:53, 59, 65 or 71.

70. (new) The antibody of claim 59 further comprising a VL CDR3 having an amino acid sequence of SEQ ID NO:54, 60, 66 or 72.

71. (new) The antibody of claim 59 further comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:52, 58, 64 or 70, a VL CDR2 having an amino acid sequence of SEQ ID NO:53, 59, 65 or 71, and a VL CDR3 having an amino acid sequence of SEQ ID NO:54, 60, 66 or 72.

72. (new) The antibody of claim 65, 66 or 67 further comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:52, 58, 64 or 70.

73. (new) The antibody of claim 65, 66 or 67 further comprising a VL CDR2 having an amino acid sequence of SEQ ID NO:53, 59, 65 or 71.

74. (new) The antibody of claim 65, 66 or 67 further comprising a VL CDR3 having an amino acid sequence of SEQ ID NO:54, 60, 66 or 72.

75. (new) The antibody of claim 65 or 66 further comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:52, 58, 64 or 70, a VL CDR2 having an amino acid sequence of SEQ ID NO:53, 59, 65 or 71, and a VL CDR3 having an amino acid sequence of SEQ ID NO:54, 60, 66 or 72.

76. (new) The antibody of claim 67 further comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:52, 58, 64 or 70, a VL CDR2 having an amino acid sequence of SEQ ID NO:53, 59, 65 or 71, and a VL CDR3 having an amino acid sequence of SEQ ID NO:54, 60, 66 or 72.

77. (new) The antibody of claim 60 further comprising a VH CDR3 having an amino acid sequence of SEQ ID NO:50, 56, 62 or 68.

78. (new) The antibody of claim 60 further comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:52, 58, 64 or 70.

79. (new) The antibody of claim 60 further comprising a VL CDR2 having an amino acid sequence of SEQ ID NO:53, 59, 65 or 71.

80. (new) The antibody of claim 60 further comprising a VL CDR3 having an amino acid sequence of SEQ ID NO:54, 60, 66 or 72.

81. (new) The antibody of claim 60 or 77 further comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:52, 58, 64 or 70, a VL CDR2 having an amino acid sequence of SEQ ID NO:53, 59, 65 or 71, and a VL CDR3 having an amino acid sequence of SEQ ID NO:54, 60, 66 or 72.

82. (new) The antibody of claim 61 further comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:52, 58, 64 or 70.

83. (new) The antibody of claim 61 further comprising a VL CDR2 having an amino acid sequence of SEQ ID NO:53, 59, 65 or 71.

84. (new) The antibody of claim 61 further comprising a VL CDR3 having an amino acid sequence of SEQ ID NO:54, 60, 66 or 72.

85. (new) The antibody of claim 61 further comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:52, 58, 64 or 70, a VL CDR2 having an amino acid sequence of SEQ ID NO:53, 59, 65 or 71, and a VL CDR3 having an amino acid sequence of SEQ ID NO:54, 60, 66 or 72.

86. (new) A substantially purified antibody comprising a VH CDR1 having an amino acid sequence of a VH CDR1 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442, patent deposit Number PTA-2443, patent deposit Number PTA-2444, or patent deposit Number PTA-2445, wherein said antibody immunospecifically binds to a TANGO 268 antigen.

87. (new) A substantially purified antibody comprising a VH CDR2 having an amino acid sequence of a VH CDR2 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442, patent deposit Number PTA-2443, patent deposit Number PTA-2444, or patent deposit Number PTA-2445, wherein said antibody immunospecifically binds to a TANGO 268 antigen.

88. (new) A substantially purified antibody comprising a VH CDR3 having an amino acid sequence of a VH CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442, patent deposit Number PTA-2443, patent deposit Number PTA-2444, or patent deposit Number PTA-2445, wherein said antibody immunospecifically binds to a TANGO 268 antigen.

89. (new) A substantially purified antibody comprising a VL CDR1 having an amino acid sequence of a VL CDR1 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442, patent deposit Number PTA-2443, patent deposit Number PTA-2444, or patent deposit Number PTA-2445, wherein said antibody immunospecifically binds to a TANGO 268 antigen.

90. (new) A substantially purified antibody comprising a VL CDR2 having an amino acid sequence of a VL CDR2 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442, patent deposit Number PTA-2443, patent deposit Number PTA-2444, or patent deposit Number PTA-2445, wherein said antibody immunospecifically binds to a TANGO 268 antigen.

91. (new) A substantially purified antibody comprising a VL CDR3 having an amino acid sequence of a VL CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442, patent deposit Number PTA-2443, patent deposit Number PTA-2444, or patent deposit Number PTA-2445, wherein said antibody immunospecifically binds to a TANGO 268 antigen.

92. (new) The antibody of claim 86 further comprising a VH CDR2 having an amino acid sequence of a VH CDR2 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442, patent deposit Number PTA-2443, patent deposit Number PTA-2444, or patent deposit Number PTA-2445, wherein said antibody immunospecifically binds to a TANGO 268 antigen.

93. (new) The antibody of claim 86 further comprising a VH CDR3 having an amino acid sequence of a VH CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442, patent deposit Number PTA-2443, patent deposit Number PTA-2444, or patent deposit Number PTA-2445.

94. (new) The antibody of claim 86 further comprising:

- (a) a VH CDR2 having an amino acid sequence of a VH CDR2 encoded by the cDNA insert of the plasmid deposited with the ATCC® as

patent deposit Number PTA-2442, patent deposit Number PTA-2443, patent deposit Number PTA-2444, or patent deposit Number PTA-2445; and

- (b) a VH CDR3 having an amino acid sequence of a VH CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442, patent deposit Number PTA-2443, patent deposit Number PTA-2444, or patent deposit Number PTA-2445.

95. (new) The antibody of claim 86 further comprising a VL CDR1 having an amino acid sequence of a VL CDR1 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442, patent deposit Number PTA-2443, patent deposit Number PTA-2444, or patent deposit Number PTA-2445.

96. (new) The antibody of claim 86 further comprising a VL CDR2 having an amino acid sequence of a VL CDR2 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442, patent deposit Number PTA-2443, patent deposit Number PTA-2444, or patent deposit Number PTA-2445.

97. (new) The antibody of claim 86 further comprising a VL CDR3 having an amino acid sequence of a VL CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442, patent deposit Number PTA-2443, patent deposit Number PTA-2444, or patent deposit Number PTA-2445.

98. (new) The antibody of claim 86 further comprising:

- (a) a VL CDR1 having an amino acid sequence of a VL CDR1 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442, patent deposit Number PTA-2443, patent deposit Number PTA-2444, or patent deposit Number PTA-2445;
- (b) a VL CDR2 having an amino acid sequence of a VL CDR2 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent

- deposit Number PTA-2442, patent deposit Number PTA-2443, patent deposit Number PTA-2444, or patent deposit Number PTA-2445; and
- (c) a VL CDR3 having an amino acid sequence of a VL CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442, patent deposit Number PTA-2443, patent deposit Number PTA-2444, or patent deposit Number PTA-2445.

99. (new) The antibody of claim 92, 93 or 94 further comprising a VL CDR1 having an amino acid sequence of a VL CDR1 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442, patent deposit Number PTA-2443, patent deposit Number PTA-2444, or patent deposit Number PTA-2445.

100. (new) The antibody of claim 92, 93 or 94 further comprising a VL CDR2 having an amino acid sequence of a VL CDR2 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442, patent deposit Number PTA-2443, patent deposit Number PTA-2444, or patent deposit Number PTA-2445.

101. (new) The antibody of claim 92, 93 or 94 further comprising a VL CDR3 having an amino acid sequence of a VL CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442, patent deposit Number PTA-2443, patent deposit Number PTA-2444, or patent deposit Number PTA-2445.

102. (new) The antibody of claim 92 or 93 further comprising:

- (a) a VL CDR1 having an amino acid sequence of a VL CDR1 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442, patent deposit Number PTA-2443, patent deposit Number PTA-2444, or patent deposit Number PTA-2445;
- (b) a VL CDR2 having an amino acid sequence of a VL CDR2 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442, patent deposit Number PTA-2443, patent deposit Number PTA-2444, or patent deposit Number PTA-2445; and

- (c) a VL CDR3 having an amino acid sequence of a VL CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442, patent deposit Number PTA-2443, patent deposit Number PTA-2444, or patent deposit Number PTA-2445.

103. (new) The antibody of claim 94 further comprising:

- (a) a VL CDR1 having an amino acid sequence of a VL CDR1 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442, patent deposit Number PTA-2443, patent deposit Number PTA-2444, or patent deposit Number PTA-2445;
- (b) a VL CDR2 having an amino acid sequence of a VL CDR2 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442, patent deposit Number PTA-2443, patent deposit Number PTA-2444, or patent deposit Number PTA-2445; and
- (c) a VL CDR3 having an amino acid sequence of a VL CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442, patent deposit Number PTA-2443, patent deposit Number PTA-2444, or patent deposit Number PTA-2445.

104. (new) The antibody of claim 87 further comprising a VH CDR3 having an amino acid sequence of a VH CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442, patent deposit Number PTA-2443, patent deposit Number PTA-2444, or patent deposit Number PTA-2445.

105. (new) The antibody of claim 87 further comprising a VL CDR1 having an amino acid sequence of a VL CDR1 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442, patent deposit Number PTA-2443, patent deposit Number PTA-2444, or patent deposit Number PTA-2445.

106. (new) The antibody of claim 87 further comprising a VL CDR2 having an amino acid sequence of a VL CDR2 encoded by the cDNA insert of the plasmid deposited



with the ATCC® as patent deposit Number PTA-2442, patent deposit Number PTA-2443, patent deposit Number PTA-2444, or patent deposit Number PTA-2445.

107. (new) The antibody of claim 87 further comprising a VL CDR3 having an amino acid sequence of a VL CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442, patent deposit Number PTA-2443, patent deposit Number PTA-2444, or patent deposit Number PTA-2445.

108. (new) The antibody of claim 87 or 104 further comprising:

- (a) a VL CDR1 having an amino acid sequence of a VL CDR1 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442, patent deposit Number PTA-2443, patent deposit Number PTA-2444, or patent deposit Number PTA-2445;
- (b) a VL CDR2 having an amino acid sequence of a VL CDR2 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442, patent deposit Number PTA-2443, patent deposit Number PTA-2444, or patent deposit Number PTA-2445; and
- (c) a VL CDR3 having an amino acid sequence of a VL CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442, patent deposit Number PTA-2443, patent deposit Number PTA-2444, or patent deposit Number PTA-2445.

109. (new) The antibody of claim 88 further comprising a VL CDR1 having an amino acid sequence of a VL CDR1 having an amino acid sequence of a VL CDR1 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442, patent deposit Number PTA-2443, patent deposit Number PTA-2444, or patent deposit Number PTA-2445.

110. (new) The antibody of claim 88 further comprising a VL CDR2 having an amino acid sequence of a VL CDR2 having an amino acid sequence of a VL CDR2 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number

PTA-2442, patent deposit Number PTA-2443, patent deposit Number PTA-2444, or patent deposit Number PTA-2445.

111. (new) The antibody of claim 88 further comprising a VL CDR3 having an amino acid sequence of a VL CDR3 having an amino acid sequence of a VL CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442, patent deposit Number PTA-2443, patent deposit Number PTA-2444, or patent deposit Number PTA-2445.

112. (new) The antibody of claim 88 further comprising:

- (a) a VL CDR1 having an amino acid sequence of a VL CDR1 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442, patent deposit Number PTA-2443, patent deposit Number PTA-2444, or patent deposit Number PTA-2445;
- (b) a VL CDR2 having an amino acid sequence of a VL CDR2 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442, patent deposit Number PTA-2443, patent deposit Number PTA-2444, or patent deposit Number PTA-2445; and
- (c) a VL CDR3 having an amino acid sequence of a VL CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442, patent deposit Number PTA-2443, patent deposit Number PTA-2444, or patent deposit Number PTA-2445.

113. (new) A mouse monoclonal antibody produced by mouse hybridoma cell line 9012.2, 1P10.2, 8M14.3, 9E18.2 or 744.6 deposited with the ATCC® as patent deposit Number PTA-1746, patent deposit Number PTA-1747, patent deposit Number PTA-1748, patent deposit Number PTA-1749 or patent deposit Number PTA-1750.

114. (new) A substantially purified antibody comprising one or more VH CDRs having an amino acid sequence encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-1746, patent deposit Number PTA-1747, patent

deposit Number PTA-1748, patent deposit Number PTA-1749 or patent deposit Number PTA-1750.

115. (new) A substantially purified antibody comprising one or more VL CDRs having an amino acid sequence encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-1746, patent deposit Number PTA-1747, patent deposit Number PTA-1748, patent deposit Number PTA-1749 or patent deposit Number PTA-1750.

116. (new) The antibody of claim 114 further comprising one or more VL CDRs having an amino acid sequence encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-1746, patent deposit Number PTA-1747, patent deposit Number PTA-1748, patent deposit Number PTA-1749 or patent deposit Number PTA-1750.

117. (new) A substantially purified antibody comprising a VH domain having an amino acid sequence encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-1746, patent deposit Number PTA-1747, patent deposit Number PTA-1748, patent deposit Number PTA-1749 or patent deposit Number PTA-1750.

118. (new) A substantially purified antibody comprising a VL domain having an amino acid sequence encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-1746, patent deposit Number PTA-1747, patent deposit Number PTA-1748, patent deposit Number PTA-1749 or patent deposit Number PTA-1750.

119. (new) The antibody of claim 117 further comprising a VL domain having an amino acid sequence encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-1746, patent deposit Number PTA-1747, patent deposit Number PTA-1748, patent deposit Number PTA-1749 or patent deposit Number PTA-1750.

120. (new) A substantially purified scFv comprising the amino acid sequence encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit

Number PTA-2442, patent deposit Number PTA-2443, patent deposit Number PTA-2444, or patent deposit Number PTA-2445.

121. (new) A substantially purified antibody that competes with a scFv antibody encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-1746, patent deposit Number PTA-1747, patent deposit Number PTA-1748, patent deposit Number PTA-1749 or patent deposit Number PTA-1750 for binding to a TANGO 268 antigen.

122. (new) A substantially purified antibody that competes with a mouse monoclonal antibody produced by mouse hybridoma cell line 9012.2, 1P10.2, 8M14.3, 9E18.2 or 744.6 deposited with the ATCC® as patent deposit Number PTA-1746, patent deposit Number PTA-1747, patent deposit Number PTA-1748, patent deposit Number PTA-1749 or patent deposit Number PTA-1750 for binding to a TANGO 268 antigen.

123. (new) The antibody as in any one of claims 59-64, 76, 86-91, 103, 114-116, 121 or 122, wherein the antibody is a monoclonal antibody.

124. (new) The antibody as in any one of claims 59-64, 76, 86-91, 103, 114-116, 121 or 122, wherein the antibody is a human antibody.

125. (new) The antibody as in any one of claims 59-64, 76, 86-91, 103, 114-116, 121 or 122, wherein the antibody is a humanized antibody.

126. (new) The antibody as in any one of claims 59-64, 76, 86-91, 103, 114-116, 121 or 122, wherein the antibody is a Fab fragment.

127. (new) The antibody as in any one of claims 59-64, 76, 86-91, 103, 114-116, 121 or 122, wherein the antibody is an scFv.

128. (new) The antibody as in any one of claims 59-64, 76, 86-91, 103, 113-116, 121 or 122, wherein the antibody is conjugated to a therapeutic or drug moiety.